Express delivery of 100% of patients achieved complete remission, and the Phase 2 clinical results of the oncolytic virus/PD-1 antibody combination are positive

▎The content team editor of WuXi AppTec recently, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, combined with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer , These patients did not respond to BCG treatment
.

The mid-term results showed that 100% of the 9 patients who could be evaluated for efficacy achieved complete remission at the 3-month time point
.

It is worth mentioning that this innovative treatment has also been approved for clinical use in China recently, and Lepu Bio has its development rights in China
.

Oncolytic virus is a type of virus that can selectively lyse cancer cells.
On the one hand, it can infect tumor cells and cause cell lysis.
On the other hand, the molecules released during the lysis process can also induce innate and adaptive immune responses, attracting more Immune cells continue to kill the remaining tumor cells
.

In addition, many oncolytic viruses can also carry therapeutic transgenes to enhance anti-tumor efficacy
.

CG0070 is based on a modified adenovirus type 5 (Ad5) backbone, including a tumor-specific promoter, and a granulocyte-macrophage colony stimulating factor (GM-CSF) transgene
.

After lysing tumor cells, GM-CSF is released along with tumor-specific antigens and other danger signals
.

GM-CSF can activate dendritic cells (DC), DC cells recognize tumor antigens and present them to cytotoxic and helper T cells, thereby promoting their maturation
.

These T cells can then circulate throughout the body, identifying and attacking the remaining tumor cells
.

▲The mechanism of action of CG0070 (picture source: CG Oncology official website) preliminary clinical trial results show that as of November 8, 2021, 100% of patients (n=9) who reached the 3-month assessment point achieved complete remission, and at the same time reached 6 Among patients at the monthly assessment point (n=6), all patients maintained complete remission, and the complete remission rate of patients who reached the 9-month assessment point was still 100% (n=3)
.

In terms of safety, treatment-related adverse events were limited to temporary grade 1-2 local urogenital symptoms and immune-related adverse events, and no treatment-related adverse events or serious adverse events above grade 3 were found
.

"These preliminary results are exciting
.

" said the lead investigator of the trial, Dr.
Roger Li, a urological oncologist at the Moffitt Cancer Center.
"If similar trends are maintained, we may bring transformative treatments to patients who do not respond to BCG
.

"Reference: [1] CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.
Retrieved November 14, 2021, from https:// Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a recommended treatment plan
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.